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Smumary A total of 155 samples from 101 patients with ovarian cancer were investigated using flow
cytometry to evaluate the DNA index and the percentage of cells in the various cell cycle phases. Thirty-four
samples were DNA diploid tumours, while the other 121 were DNA aneuploid tumours. The DNA index was
very stable in different sites and over time in the same patient. Tumour stage and ploidy were significantly
associated: stages III and IV tumour stage were more likely to be DNA aneuploid. Patients with residual
tumour size at first surgery >2cm had a significantly larger number of DNA aneuploid than DNA diploid
tumours. The DNA index was also related to the degree of differentiation of the tumours. The percentage of
cells in the S phase of the cell cycle was significantly higher in DNA aneuploid and in poorly differentiated
tumours than DNA diploid and well differentiated tumours. Multivariate analysis using the Cox model
showed that the DNA index and the percentage of cells in S phase were not independent prognostic variables
in this study. Prospectively collected data should be accumulated before assigning the DNA index an
important role as a biological prognostic factor in ovarian cancer.
Flow cytometry has recently been employed to determine the
DNA content of human neoplastic cell populations and the
percentage of cells in the cell cycle phases. For some
tumours flow cytometry data have proved valuable as a
prognostic indicator. The DNA content of tumour cells
appeared to be related to their differentiation (better
differentiated tumours were more likely to be DNA diploid
whereas anaplastic tumours had DNA aneuploid content)
(Laerum & Farsund, 1981; Frankfurt et al., 1984a;
Friedlander et al., 1984a; Johnson et al., 1985; Coon et al.,
1987) and a good correlation has been found between DNA
index and survival (Coulson et al., 1984; Volm et al., 1985a;
Frankfurt et al., 1986; Zimmerman et al., 1987).
There are conflicting results on the prognostic meaning of
flow cytometric parameters in ovarian cancers possibly
because of the small series investigated so far (Frankfurt et
al., 1986; Friedlander et al., 1984b; Rodenburg et al., 1987).
In this study we assessed the ploidy level and the percentage
of cells in the various cell cycle phases on tumour tissue
from 101 patients with ovanran carcinoma. The relationship
between flow cytometric data, the pathological and clinical
features of the tumour were investigated.
Materials and methods
Flow cytometric analysis was performed on 155 specimens
from 101 ovarian carcinoma patients. Out of 101 patients, 30
(29%) had received chemotherapy. The majority of them
were treated either with cisplatinum alone, (12 cases) or with
cisplatinum, adriamycin and cyclophosphamide (10 cases).
The patients' main characteristics are summarised in Table I.
All patients were classified by FIGO criteria for staging
(Young et al., 1982). Histological grading of tumours was
evaluated in terms of well (1/3), moderately (2/3) and poorly
differentiated (3/3) and according to Broders' criteria (Long
& Sommers, 1969; Ozols et al., 1980).
The DNA content and the percentage of cells in the S
phase of the cell cycle were analysed on primary tumours
and on metastases after primary surgery or second look
laparotomy and on ascitic fluids after paracentesis.
Primary tumours or metastases were collected in PBS
containing lOOUml-' penicillin and lOO1gml1- strepto-
mycin (Gibco Europe, Glasgow, UK) and processed a few
hours after collection. Tissues were divided up and fragments
were washed with PBS to eliminate debris or blood coaguli.
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Table I Clinical and pathological features of the 101 patients in the
study
Performance status
FIGO stage
Residual tumour after surgery
Histology
Gradings:
well differentiated
moderately differentiated
poorly differentiated
n.a.
Broders' criteria
60
70
80
90
100
IA
IB
IC
II
III
IV
<2cm
>2cm
n.a.
serous
endometrioid
mucinous
undifferentiated
n.a.
14
24
3/4
44
n.a.
No. cases
1
8
28
16
48
2
1
4
4
75
15
19
74
8
65
16
7
9
4
13
26
52
10
3
13
33
41
11
n.a.=Data not available.
Soft tissue tumours were then disaggregated with 0.25%
tripsin 1:250 (Difco, Michigan, USA) in PBS without cal-
cium and magnesium for 30min at 37TC in a baffled flask on
a magnetic stirrer. Hard tumours were minced into small
fragments then treated for 1 h at 37°C with collagenase type
1 (Sigma Chemical Company, St Louis, USA) dissolved in
medium RPMI without serum. Cell suspensions were then
filtered through 8-10 layers of gauze, washed and re-
suspended in Hanks's solution.
Ascitic fluids were collected in heparinised bottles and
centrifuged at 200g for 10min to separate the cellular phase.
The pellet was resuspended in 20ml PBS and layered on a
discontinuous gradient of 100% Fycoll-Hypaque for 20min at
600g to separate tumour cells from erythrocytes and mono-
nuclear cells. The tumour cells in the upper layer of the
gradient were then freed of macrophages by adhesion on
plastic surface of tissue flasks. A second gradient of one
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75% and one 100% Fycoll-Hypaque was made to separate
cancer cells from lymphocytes. After this step ascitic cells
were washed twice with PBS and resuspended in Hank's
solution.
For flow cytometry analysis, the samples were stained with
propidium iodide (PI) (Calbiochem Behring Co., USA) by
adding 2ml of PI solution (50pgml-1 PI in 0.1% sodium
citrate containing 25pi 0.1% Nonidet P 40 detergent (Sigma)
and 25ul RNAse 0.5mgml-l (Calbiochem Behring, Co,
USA)) to 200-300yl of cell suspension (5 x I05 cells ml-l) at
room temperature for at least 60min. The suitability of the
preparation and the absence of aggregates were checked by
fluorescence microscopy before the sample was run.
Human leukocytes from freshly collected blood were used
as standard to determine the DNA index. A standard was
run before and after the tumour sample to check for drifting
of the laser output. Doublets were less than 1% by morpho-
logical examination of the tumour cell suspension, and
leukocyte standard always contained less than 0.8% of
doublets.
Cytofluorometric analysis was performed using a 30L
Cytofluorograph (Ortho Instruments, USA). The fluores-
cence pulses were detected in a spectrum range between 580
and 750 nm. The coefficient of variation (CV) of the
standard was between 1.5 and 2.5% and in ovarian cancer
cells the CV of the GI peak was 3-4%. At least 50,000 cells
were measured by flow cytometry at the rate of 500cells s-
(Erba et al., 1985).
Ploidy was expressed as DNA index, representing the ratio
between the G, peak of ovarian cancer cells and the GO/GI
peak of leukocytes (Barlogie et al., 1983). The percentage of
cells in the cell cycle phases was evaluated in only 73 out of
155 samples (because of the presence of more than one cell
population causing overlapping of the cell cycle phases or
because the number of cancer cells was too small for a good
estimate of the cell cycle phases) and was calculated by the
method of Baisch (Baisch et al., 1975). The Mann-Whitney
test was used for statistical analysis of the percentage of the
cells in the synthesis (S) phase of the cell cycle (Giannangeli
et al., 1983). Time on study or time to death was calculated
from the day of first surgery to the cut-off date or to death,
if this occurred. The life-tables method (Kaplan & Meier,
1958) and the log-rank statistic (Tarone & Ware, 1977)
were used respectively to estimate and compare survival
curves. In order to evaluate to what extent the probability of
a better survival depends on ploidy and/or percentage of
cells in S phase and other explanatory variables, a multi-
variate analysis on survival was also done applying the Cox
model (Cox, 1972). In this analysis the main effects of ploidy
and/or percentage of cells in S phase and of prognostic
variables, as well as the effects of the first order interactions
of the latter, were investigated. A stepwise procedure was
adopted to select the final most parsimonious model contain-
ing the statistically significant sub-sets of variables and
interactions.
Results
The DNA index was evaluated on 155 samples from 101
patients, as in 26 patients it was possible to make more than
one DNA analysis. In 34 samples, eight pimary tumours, 22
ascitic fluids and four omental metastases, the DNA index
was 1.00 (DNA diploid tumours) while in the other 121
samples, 26 primary tumours, 79 ascitic fluids and 16
metastases, the DNA index was between 0.85 and 3.00
(DNA aneuploid tumours). Four were DNA tetraploid
tumours and only two had a DNA index lower than the
DNA diploid tumours. Figure I shows representative DNA
histograms of different samples with different DNA index.
As shown in Table II, five patients had more than one
aneuploid cell population and were classified as DNA multi-
clonality (Figure 2); in patient no. 24 there were two cell
clones in the primary tumour and in ascitic fluid, with
different DNA indices.
As described, from 26 patients DNA content was mea-
sured on several samples to check the stability of the DNA
index over time and from different lesions. Except for
patient no. 5, the DNA index was very stable in different
samples (Table E). Patient no. 46 was monitored over 30
months, no. 91 over 5 months.
When the DNA index was correlated with the stage of the
primary carcinoma of the ovary according to FIGO, we
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Fgwe I Typical flow cytometric analysis of the DNA content
of human ovarian cancer cells. a, DNA index=1.00, b, DNA
index=0.90, c, DNA index=1.30; d, DNA index =2.00.
Table H DNA multiclonality: the six specimens with
neoplastic cells of two different DNA indices
Patient no. Sanples DNA index
20 Ascitic fluid 1.24 and 1.53
21 Primary tumour 1.65 and 1.70
24 Primary tumour 0.85 and 1.60
24 Ascitic fluid 0.85 and 1.60
39 Ascitic fluid 1.42 and 1.68
101 Primary tumour 1.39 and 2.30
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Tabie IV Distribution of DNA diploid and DNA aneuploid
tumours and the degree of differentiation of the tumours
DNA dploid DNA oneuploid
tumours twnours
Tumow classfication (cases) (cases)
Well differentiated 4 6
Moderately differentiated 7 15
Poorly differentiated 14 41
Broders' 1/4 1 1
Broders' 2/4 6 8
Broders' 3/4 7 22
Broders' 4/4 11 36
o 40 80 120 160 200
DNA content (relative fluorescence)
Figwe 2 Example of DNA multiclonality: the arrows indicate
the G1 peaks of different DNA aneuploid tumours with different
DNA indices. Between the two is theG0/G, peak of normal cells
present in the tumour. DNA index=0.85-1.60.
Table m DNA index of ovarian tumour cells obtained from
different sites and/or in repeated samplings in the same patient
Patient Primyr DNA index Ascitic
no. tumour in metastases fluid
3 1.89 1.91
4 1.00 1.00
5 1.15 1.72(2)
13 1.68 1.68
16 1.67(2)
17 1.35 1.24
24 0.85-1.60 0.85-1.60
25 1.80(8)
32 1.30(2)
33 1.60(2)
35 2.00 2.00(2)
39 1.42-1.68
1.68(9)
40 1.60 1.60
45 1.20 1.20
46 1.00 1.00(4)
49 1.20 1.20 1.20
51 0.90 0.90
66 1.00(2)
67 1.50 1.50
74 1.65 1.65
76 1.90(4)
80 1.60(2)
81 1.75 1.75
88 1.00(2)
91 1.80 1.80(7)
100 1.87 1.87 1.87
In parentheses are the number of samples analysed.
found that in stages III and IV there were significantly more
DNA aneuploid tumours (P<0.01) than DNA diploid
tumours: respectively 63 and 19. Not enough data were
available on tumours classified as Ia, lb, Ic and II for
statistical analysis; nevertheless 7 out of 8 were DNA diploid.
The DNA index was also correlated with the histological
grading of the tumours from 92 patients. As shown in Table
IV, poorly differentiated tumours and/or tumours classified
as 4/4 accordng to Broders' criteria were more likely to be
DNA aneuploid tumours.
DNA diploid or aneuploid tumours were correlated with
the residual tumour size (Table V). Patients with residual
tumours smaller than 2cm had the same number of tumours
with DNA diploid or aneuploid content, but in patients
where the residual tumours were larger than 2cm, there were
significantly more DNA aneuploid tumours than DNA
diploid tumours, 58/16 respectively (P<0.01). No clusters
were found in DNA index for different histological types.
Table V Distribution of DNA diploid and DNA aneuploid
tumours in relation to residual tumour size at first surgery
Residual twnour size (cases)
62cm >2cm
DNA diploid tumours 11 8
DNA aneuploid tumours 16 58a
aP<O.Ol statistical significanCe (2 test) in respect to DNA diploid
tumours in the group of >2cm.
The percentage of cells in the S phase of the cell cycle was
calculated on 73 out of 155 samples run through flow
cytometry. There was a significantly lower proportion of
cells in S phase in DNA diploid tumours than in DNA
aneuploid ones (median 5.05% vs 13.45% respectively;
P<0.01). This difference was clear cut when comparing
DNA diploid and DNA aneuploid cells present in ascitic
fluids, with 2.96 and 14.86% of the cells in the S phase
respectively (P<0.01).
The percentage of cells in the S phase was also correlated
with the histological grading of the tumours (Table VI).
Poorly differentiated tumours and/or tumours classified as
4/4 according to Broders' criteria seemed to have a higher
percentage of cells in the S phase of the cell cycle than
moderately or well differentiated tumours or 3/4, 2/4, 1/4
Broders'. The samples studied did not show different
percentages of cells in the S phase in relation to the
histological type.
Univariate analysis on survival and DNA index was
performed on the whole population of 90 patients with
stages III and IV (Figure 3). At two years the proportion of
Table VI Percentage of cells in the S phase of the cell cycle
in relation to the degree of differentiation of the tumours
% cells in S phase
Tumour classifcation +s.d.
Well differentiated tumours 6.9+4.2
Moderately differentiated tumours 10.0+8.2
Poorly differentiated tumours 15.7+7.3
Broders' 114 7.2+6.7
Broders' 2/4 7.1+3.5
Broders' 3/4 12.7+9
Broders' 4/4 17.0+7.7
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Fgwe 3 Survival curves for patients with stage III and IV with
DNA diploid or DNA aneuploid tumours.
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long-term survivors was considerably higher in the DNA
diploid tumour group: 62% (95% confidence limits 44-79)
compared to 32% (95% confidence limits 21-43). This
difference, however, was not statistically significant
(P=O.ll). When results were adjusted for size of residual-
tumour after first surgery (<2cm or >2cm) or FIGO stage
(I and II vs III-and IV), patients with a DNA diploid
tumour again had a better survival but the difference was
not significant in either subgroup (data not shown).
Analysis of survivaL according to the percentage of cells in
the S phase was possible only in a subset of 68 patients for
whom survival data were available. Patients with a high
percentage of cells in S phase (>5%) had a survival that
was not statistically different from that of patients with a
low percentage (Figure 4). As with the DNA content the
difference became less recognisable when data were adjusted
for independent prognostic variables such as residual tumour
size and FIGO stage (data not shown).
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Fugwe 4 Survial curves for patients with stage Ill and IV with
a high (>5%) or low percentage (<5%) of tumour cells in the S
phase of the cell cycle.
To study the concomitant effects of several known prog-
nostic factors on survival and their relationship with the
DNA index, multivariate analysis was performed on 79 of-
the 90 patients with advanced tumour (stages III and IV) for
whom all the following variables were available: age, residual
tumour size (<2cm, >2cm), histological type and gradings.
Only stage and histological type had a significant impact on
survival. The risk of dying increased by factors of, respec-
tively, 2.4 and 1.9 with stage IV and histotype other than
serous. All other variables, including DNA index and resi-
dual tumour size, had no additional prognostic value as
regards survival.
ENcsion
From 101 ovarian carcinoma patients, 155 samples were
studied by flow cytometry and evaluated for DNA content.
Thirty-four (22%) were DNA diploid tumours and 121
(78%) were DNA aneuploid tumours, as already observed
for this type of tumour (Friedlander et al., 1984b,c; Hedley
et al., 1985; Volm et al., 1985b) and other types (Barlogie et
al., 1980; Frankfurt et al., 1986; Cornelisse et al., 1987).
Considering the high percentage of DNA diploid ovarian
tumours one may wonder whether they are overestimated
because of the predominance of normal cells present in the
sample analysed by flow cytometry. In order to exclude this
possibility, we made a cytological analysis of each sample.
An atypical cell population was often mixed with contami-
nating normal cells (particularly in the ascitic fluids); and the
ratio differed from one sample to another. In many DNA
diploid tumours, the ratio of normal to atypical cells was in
favour of the contaminating normal cells. In none of the
DNA diploid tumours analysed, however, was the per-
centage of tumour cells less than 10%. As we are confident
that in our conditions we can detect aneuploid cells even
when present in a lower proportion (e.g. in experiments in
which we mixed 99% DNA diploid cells and 1% of DNA
aneuploid cells, the DNA aneuploid cell population was
detectable), we think it is reasonable to drop the hypothesis
that the DNA diploid tumours are an artificial result due to
the limit of the method used.
In six samples we found more than one cancer cell
population with a different DNA index (Table II and Figure
2). This was in agreement with the findings of other groups
for this type of tumour (Frankfurt et al., 1984a; Rodenburg
et al., 1987). The number of cases with DNA multiclonality
was too small for assessing whether the presence of different
neoplastic cell populations with different DNA indices has
any meaning in terms of biological and clinical behaviour of
the tumour.
The stability of the DNA index over tine and in different
klsions, monitored in 25 patients, proved to be the same in
primary tumour, metastases and ascitic fluids from the same
patients and also when many paracenteses were performed
over time (see Table Ill), indicating some degree of stability
of the malignant genoma (Frankfurt et al., 1984a,c; Volm et
al., 1985a; Iversen & Skaarland, 1987). The DNA index
seems to be a very constant feature in ovarian carcinoma
and could be considered one of the markers for defining
metastatic cells.
A good correlation was found between DNA index and
FIGO stage: patients with stage III and IV more frequently
had DNA aneuploid tumours, while patients with stage I
and II were more likely to have DNA diploid tumours
(Iversen & Laerum, 1985).
That DNA index may be indicative of the degree of
malignancy is also suggested by the finding that it was
related to the degree of differentiation of the tumour (Table
IV). Ploidy distribution in tumour samples was related to the
size of the residual tumour in the peritoneal cavity after
surgery (Table V). Our data are in agreement with those
reported by Rodenburg et al. (1987), who found that
patients with DNA diploid tumours more frequently had
residual tumours smaller than 1.5cm.
Since the DNA index appears stable in the same tumour
over time one can speculate that smaller tumours that can be
almost completely eradicated surgically leaving a residual
tumour less than 2cm are intrinsically different, perhaps less
malignant, from those that are larger at diagnosis. In other
words, the post-surgical residual tumour (<or >2cm) does
not depend only on how early the diagnosis is made but may
be inherently associated with the biological properties of the
tumour.
DNA diploid tumours had a significantly lower percentage
of cells in the S phase than DNA aneuploid tumours, as
reported by other authors (Friedlander et al., 1983, 1984c;
Frankfurt et al., 1984b, 1986; Iversen & Skaarland, 1987).
Even though the flow cytometric measurement of cells in the
S phase does not give information on the kinetic parameters
of the duration of the cell cycle phase, it could give an
estimate of the proliferative activity of the tumour, as
reported by Costa et al. (1981), who found a good cor-
relation between the estimation of proliferative activity using
flow cytometry and autoradiography.
On the other hand, differences in the mean S phase
between DNA diploid and DNA aneuploid tumours could
well be affected by the fact that normal cells contained
within a tumour may contribute to the lower S phase found
in the DNA diploid tumours, and the higher value of the S
phase in the DNA aneuploid tumours could to some extent
be explained by an overlap of S and G2M phases of the
diploid normal cells (Friedlander et al., 1983).
When compared to the degree of malignancy (Table VI),
high S phase values were well correlated with poorly
differentiated tumours and with tumours classified as
Broders' 4/4, suggesting that flow cytometric measurement of
the S phase may provide confirmation of the cytological
gradings in defining the degree of malignancy in these
tumours.
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In contrast to reports by Friedlander and other groups
(Friedlander et al., 1984b; Rodenburg et al., 1987) but in
agreement with others (Hedley et al., 1985; Frankfurt et al.,
1986), we found that the DNA index was not of major
importance as a prognostic factor in ovanran carcinoma.
Patients with DNA diploid tumours survived longer than
patients with DNA aneuploid tumours, but the difference
was not statistically significant, nor was it confirmed by Cox
analysis, which corrects for all other recognised prognostic
factors in ovarian cancer. Patients with a higher percentage
of cells in S phase survived longer than patients with a lower
percentage of S phase cells (Figure 4), but not significantly,
as Cox analysis did show.
In contrast to the large knowledge existing of many other
human tumours, for ovarian cancers not much information
is available on the relationship between the proportion of S
phase cancer cells and survival of the patients. In the present
study we did not find any statistical difference in the survival
of patients with a low (5%) or high (>5%) fraction of cells
in S phase. These data are essentially consistent with those
reported previously by Volm et al. (1985) who found that 10
patients with a S-G2M fraction smaller than 17% did not
survive longer than 14 patients with a larger percentage of
cells in S-G2M phase. Also Frankfurt did not find signifi-
cant influence of S phase index for the survival of patients in
35 cases of DNA aneuploid tumours (Frankfurt et al., 1986).
Direct comparison of our data with the results of similar
studies is extremely difficult because of heterogeneity in the
choice of the variables used to fit the regression model, and
the different numerical distribution of the patients when
stratified by those variables. Our analysis studied the com-
bined impact on survival of ploidy, tumour size, FIGO
staging, grading, histotype and age. Other authors
(Rodenburg et al., 1987) considered the presence of ascites,
peritoneal carcinosis and size of metastasis in addition but
excluded age. Among these factors stage and residual
tumour size after first surgery are probably the most impor-
tant. In our series we were unable to find any prognostic
significance for tumour size, which in a similar analysis
conducted in a much larger population of >500 patients
(GICOG, 1987) was the most important determinant for
prognosis. Possibly our small sample and the larger number
of variables tested may have resulted in an unrealistic
definition of apparent correlations. In populations studied by
other authors, not larger than ours, conventionally recog-
nised determinants, such as tumour size, also lose their
prognostic value. Thus the discrepancy in results is likely to
be due to the relatively small series of each study and
prospectively collected data should be accumulated before
assigning the DNA index a major role as a biological
prognostic factor in ovarian cancer.
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